Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Q1 2025 vs. Q4 2024
How the institutions holding Innate Pharma SA changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 9 | 10 | +1 |
| Shares | 138.0K | 158.2K | +20.2K (+14.7%) |
| Value | $254.8K | $281.6K | +$26.8K (+10.5%) |
New holders (3)
Institutions that held Innate Pharma SA at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 15,326 | $27.3K | 0.00% |
| GAMMA Investing LLC | 2,233 | $3.98K | 0.00% |
| Tower Research Capital LLC (TRC) | 3 | $5 | 0.00% |
Sold out (2)
Institutions that held Innate Pharma SA at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| National Bank of Canada | 450 | $828 |
| Steward Partners Investment Advisory, LLC | 200 | $368 |